Nothing Special   »   [go: up one dir, main page]

CL2015002669A1 - Polipeptidos que contienen región fc aglicosilada - Google Patents

Polipeptidos que contienen región fc aglicosilada

Info

Publication number
CL2015002669A1
CL2015002669A1 CL2015002669A CL2015002669A CL2015002669A1 CL 2015002669 A1 CL2015002669 A1 CL 2015002669A1 CL 2015002669 A CL2015002669 A CL 2015002669A CL 2015002669 A CL2015002669 A CL 2015002669A CL 2015002669 A1 CL2015002669 A1 CL 2015002669A1
Authority
CL
Chile
Prior art keywords
aglycosylated
region
polypeptides containing
present
gycosilate
Prior art date
Application number
CL2015002669A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2015002669A1 publication Critical patent/CL2015002669A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PROPORCIONAN EN LA PRESENTE MOLÉCULAS IgG1 Fc HUMANAS VARIANTES QUE CARECEN O CON FUNCIÓN EFECTORA SUMAMENTE REDUCIDA Y ALTA ESTABILIDAD A PESAR DE QUE CARECE DE GLICOSILACION EN N297. TAMBIÉN, SE PROPORCIONAN EN LA PRESENTE PÉPTIDOS LIGADORES QUE SO GICOSILAN CUANDO SE EXPRESAN EN LAS CÉLULAS DE MAMIFERO.
CL2015002669A 2013-03-14 2015-09-14 Polipeptidos que contienen región fc aglicosilada CL2015002669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784669P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CL2015002669A1 true CL2015002669A1 (es) 2016-09-09

Family

ID=50680166

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015002686A CL2015002686A1 (es) 2013-03-14 2015-09-14 Muteínas de interleucina-2 para la expansion de células t reguladoras
CL2015002669A CL2015002669A1 (es) 2013-03-14 2015-09-14 Polipeptidos que contienen región fc aglicosilada

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015002686A CL2015002686A1 (es) 2013-03-14 2015-09-14 Muteínas de interleucina-2 para la expansion de células t reguladoras

Country Status (40)

Country Link
US (8) US9580486B2 (es)
EP (2) EP2970423B1 (es)
JP (5) JP6450365B2 (es)
KR (4) KR102219124B1 (es)
CN (2) CN105143253B (es)
AP (1) AP2015008737A0 (es)
AR (1) AR095541A1 (es)
AU (2) AU2014236281B2 (es)
BR (1) BR112015022440B1 (es)
CA (3) CA2905141A1 (es)
CL (2) CL2015002686A1 (es)
CR (2) CR20200004A (es)
CY (2) CY1121767T1 (es)
DK (2) DK2970441T3 (es)
EA (2) EA032863B1 (es)
ES (2) ES2737598T3 (es)
HK (1) HK1220695A1 (es)
HR (2) HRP20190970T1 (es)
HU (2) HUE044321T2 (es)
IL (2) IL241349B (es)
JO (1) JO3796B1 (es)
LT (2) LT2970423T (es)
MA (2) MA38477B1 (es)
ME (2) ME03437B (es)
MX (2) MX366854B (es)
MY (2) MY202248A (es)
NZ (1) NZ751148A (es)
PE (1) PE20151763A1 (es)
PH (1) PH12015502051B1 (es)
PL (2) PL2970441T3 (es)
PT (2) PT2970423T (es)
RS (2) RS58854B1 (es)
SG (2) SG11201507574VA (es)
SI (2) SI2970441T1 (es)
TN (1) TN2015000416A1 (es)
TR (2) TR201910802T4 (es)
TW (3) TWI687435B (es)
UA (1) UA119140C2 (es)
UY (1) UY35454A (es)
WO (2) WO2014153111A2 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN104870474B (zh) * 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
TR201809571T4 (tr) 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
PE20151923A1 (es) 2013-03-15 2016-01-14 Amgen Inc Anticuerpos humanos pac1
EA034350B1 (ru) 2014-02-06 2020-01-30 Ф.Хоффманн-Ля Рош Аг Слитые белки, содержащие интерлейкин-2, и их применения
PL3172227T3 (pl) * 2014-07-21 2020-04-30 Delinia, Inc. Cząsteczki, które selektywnie aktywują regulatorowe komórki T, do leczenia chorób autoimmunologicznych
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
EP4382535A3 (en) * 2014-12-15 2024-08-21 Washington University Compositions and methods for targeted cytokine delivery
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CA2982362A1 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
BR112017021696A2 (pt) * 2015-04-10 2018-07-10 Amgen Inc muteínas de interleucina-2 para a expansão de células t regulatórias
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EP3390447A1 (en) 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN109311979A (zh) * 2016-02-03 2019-02-05 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
BR112018015715A2 (pt) * 2016-02-03 2019-02-05 Amgen Inc construtos de anticorpo de engate de célula t biespecífica bcma e cd3
US11053293B2 (en) 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
CN107287273B (zh) * 2016-03-31 2021-03-09 复旦大学附属妇产科医院 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2017220704A1 (en) 2016-06-22 2017-12-28 David Klatzmann Genetically modified t lymphocytes
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
CA3041334A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
WO2018106885A1 (en) 2016-12-07 2018-06-14 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CA3064435A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
KR20200059281A (ko) 2017-10-04 2020-05-28 암젠 인크 트랜스타이레틴 면역글로불린 융합
KR20200086722A (ko) 2017-11-21 2020-07-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CA3083941A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Il-2 muteins and uses thereof
EP3720871A4 (en) * 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
JP7275049B2 (ja) 2017-12-27 2023-05-17 協和キリン株式会社 Ｉｌ－２改変体
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
SG11202007221QA (en) 2018-02-01 2020-08-28 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
EP3752178A1 (en) 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
EP3774861A1 (en) 2018-03-28 2021-02-17 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
AU2019283621B2 (en) 2018-06-07 2023-03-30 Korea Research Institute Of Bioscience And Biotechnology Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019246392A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
CN112584859A (zh) 2018-07-02 2021-03-30 美国安进公司 抗steap1抗原结合蛋白
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CA3118397A1 (en) * 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
US20220088145A1 (en) 2019-02-08 2022-03-24 The Uab Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
US11248046B2 (en) 2019-02-15 2022-02-15 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
JP2022527481A (ja) 2019-03-29 2022-06-02 アンスティテュ・クリー 生物活性が改変されたインターロイキン－２バリアント
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP3980464A1 (en) 2019-06-07 2022-04-13 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
MX2021015976A (es) 2019-07-08 2022-02-10 Amgen Inc Fusiones de inmunoglobulina y transtiretina multiespecificas.
TW202118774A (zh) * 2019-07-26 2021-05-16 美商威特拉公司 介白素-2藥劑及其用途
CR20220111A (es) * 2019-08-13 2022-05-04 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras referencia cruzada a solicitudes relacionadas
KR20220061967A (ko) 2019-09-13 2022-05-13 쿄와 기린 가부시키가이샤 DcR3 개변체
AU2020389422B2 (en) * 2019-11-20 2024-08-08 Gi Cell, Inc. Medium composition for culturing T cells and method for culturing T cells using same
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
JP2023505590A (ja) 2019-12-12 2023-02-09 イルトゥー・ファルマ インターロイキン２キメラ構築物
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
JP7303391B2 (ja) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド バイアス型ｉｌ２ムテイン、方法、および組成物
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations Inc TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
JP2023520568A (ja) * 2020-04-06 2023-05-17 ラング バイオテクノロジー ピービーシー モジュラー合成受容体及びその使用方法
GB2621482B (en) 2020-05-13 2024-09-04 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
EP4161969A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Bispecific binding constructs
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN112048018B (zh) * 2020-08-31 2021-10-08 南方医科大学 一种嵌合t细胞生长因子及其应用
AU2021369823A1 (en) 2020-10-29 2023-06-01 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
AU2021393456A1 (en) 2020-12-03 2023-06-29 Amgen Inc. Immunoglobuline constructs with multiple binding domains
MX2023006599A (es) * 2020-12-04 2023-06-19 Visterra Inc Metodos de uso de agentes de interleucina-2.
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
US20230077531A1 (en) 2021-05-27 2023-03-16 Sanofi Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
WO2023288283A2 (en) 2021-07-14 2023-01-19 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
EP4380970A1 (en) * 2021-08-06 2024-06-12 Amgen Inc. Isolation of therapeutic protein
WO2023057588A1 (en) 2021-10-06 2023-04-13 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
KR20240082411A (ko) * 2021-10-14 2024-06-10 라띠콘 (수저우) 바이오파마슈티칼스 코., 엘티디. 신규 항체-사이토카인 융합 단백질, 이의 제조 방법 및 이의 용도
IL312043A (en) 2021-10-14 2024-06-01 Teneobio Inc Mesothelin binding proteins and their uses
WO2023102463A1 (en) * 2021-12-01 2023-06-08 Visterra, Inc. Methods of using interleukin-2 agents
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
AU2023225012A1 (en) * 2022-02-22 2024-09-12 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
TW202432574A (zh) 2022-10-25 2024-08-16 比利時商艾伯霖克斯公司 具有增強的效應子功能之糖基工程化Ｆｃ變體多肽
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2024178056A1 (en) 2023-02-21 2024-08-29 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US233A (en) 1837-06-14 Improvement in plows
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0351410A1 (en) 1987-03-18 1990-01-24 3i RESEARCH EXPLOITATION LIMITED Complement-binding peptide
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
CA2062582C (en) 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
FR2752462B1 (fr) 1996-08-14 1998-10-23 Essilor Int Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
AU762382B2 (en) 1998-09-29 2003-06-26 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
CN1483041A (zh) * 2000-12-07 2004-03-17 Glp-1融合蛋白
US7259010B2 (en) 2000-12-15 2007-08-21 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region of interferon beta
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP4629047B2 (ja) * 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
BRPI0508470A (pt) 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
DK2650020T3 (en) * 2005-05-06 2017-01-16 Providence Health & Services - Oregon Trimeric OX40 immunoglobulin fusion protein and methods for applications.
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
CN101627054A (zh) * 2005-07-11 2010-01-13 马克罗基因公司 用人源化抗cd16a抗体治疗自身免疫疾病的方法
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
CA2680792A1 (en) 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
US20090016935A1 (en) 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
ES2825173T3 (es) 2009-01-21 2021-05-14 Amgen Inc Composiciones y métodos de tratamiento de enfermedades inflamatorias y autoinmunitarias
US20120100140A1 (en) * 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
MX2012007318A (es) * 2009-12-22 2012-07-20 Novartis Ag Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
AR084020A1 (es) 2010-11-30 2013-04-17 Genentech Inc Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
HUE040326T2 (hu) * 2011-02-10 2019-03-28 Roche Glycart Ag Mutáns interleukon-2 polipeptidek
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
US20150353639A1 (en) 2012-05-21 2015-12-10 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
TR201809571T4 (tr) * 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
CA2906708C (en) 2022-05-03
SI2970423T1 (sl) 2019-08-30
TWI709572B (zh) 2020-11-11
PL2970441T3 (pl) 2019-09-30
PT2970441T (pt) 2019-06-11
MA38477B1 (fr) 2019-05-31
US20180319859A1 (en) 2018-11-08
UY35454A (es) 2014-09-30
CA3149348A1 (en) 2014-09-25
KR20220101009A (ko) 2022-07-18
AU2014236316A9 (en) 2018-11-08
WO2014153111A2 (en) 2014-09-25
HK1220695A1 (zh) 2017-05-12
US10093711B2 (en) 2018-10-09
TWI687435B (zh) 2020-03-11
ES2737598T3 (es) 2020-01-15
JP2016514161A (ja) 2016-05-19
PE20151763A1 (es) 2015-12-10
AU2014236316A1 (en) 2015-10-08
KR20230157526A (ko) 2023-11-16
US9546203B2 (en) 2017-01-17
CR20150557A (es) 2015-11-10
DK2970423T3 (da) 2019-07-08
TW202115106A (zh) 2021-04-16
MX366854B (es) 2019-07-26
IL241622B (en) 2020-09-30
US11976102B2 (en) 2024-05-07
KR102418771B1 (ko) 2022-07-08
UA119140C2 (uk) 2019-05-10
EP2970441B1 (en) 2019-03-06
TW202005979A (zh) 2020-02-01
TW201522366A (zh) 2015-06-16
HRP20191075T1 (hr) 2019-09-20
SG11201507420UA (en) 2015-10-29
JO3796B1 (ar) 2021-01-31
US20170137485A1 (en) 2017-05-18
LT2970423T (lt) 2019-05-27
MA49207A1 (fr) 2021-09-30
PH12015502051A1 (en) 2016-01-18
TR201908362T4 (tr) 2019-06-21
US20170081382A1 (en) 2017-03-23
US20210094997A1 (en) 2021-04-01
CR20200004A (es) 2020-03-11
CA2905141A1 (en) 2014-09-25
EA201591766A1 (ru) 2016-02-29
US20180237489A1 (en) 2018-08-23
TWI784288B (zh) 2022-11-21
US10562950B2 (en) 2020-02-18
NZ712066A (en) 2021-05-28
RS58791B1 (sr) 2019-07-31
KR20150130342A (ko) 2015-11-23
RS58854B1 (sr) 2019-07-31
WO2014153111A3 (en) 2014-11-13
CN105358570B (zh) 2019-11-12
JP2023053148A (ja) 2023-04-12
EP2970441A1 (en) 2016-01-20
BR112015023145A2 (pt) 2017-11-21
US20140286898A1 (en) 2014-09-25
CN105358570A (zh) 2016-02-24
AU2014236281A1 (en) 2015-09-24
KR20150127185A (ko) 2015-11-16
CA3149348C (en) 2023-09-12
EA032863B1 (ru) 2019-07-31
MA38477A1 (fr) 2017-09-29
IL241349B (en) 2018-08-30
DK2970441T3 (da) 2019-06-03
CN105143253B (zh) 2021-02-19
AU2014236281B2 (en) 2018-03-08
ES2720225T3 (es) 2019-07-18
AP2015008737A0 (en) 2015-09-30
BR112015022440A2 (pt) 2017-10-24
HUE043488T2 (hu) 2019-08-28
KR102219124B1 (ko) 2021-02-22
JP2016518823A (ja) 2016-06-30
WO2014153063A1 (en) 2014-09-25
MA49207B1 (fr) 2022-08-31
IL241349A0 (en) 2015-11-30
ME03482B (me) 2020-01-20
SG11201507574VA (en) 2015-10-29
SI2970441T1 (sl) 2019-07-31
CL2015002686A1 (es) 2016-04-15
LT2970441T (lt) 2019-06-10
HUE044321T2 (hu) 2019-10-28
EA034326B1 (ru) 2020-01-28
JP2019058182A (ja) 2019-04-18
AR095541A1 (es) 2015-10-21
PT2970423T (pt) 2019-07-23
PH12015502051B1 (en) 2016-01-18
US9932380B2 (en) 2018-04-03
EA201591731A1 (ru) 2016-04-29
JP6480409B2 (ja) 2019-03-13
MX2015012890A (es) 2015-12-03
JP2021040630A (ja) 2021-03-18
TN2015000416A1 (en) 2017-01-03
MY172991A (en) 2019-12-17
CY1121767T1 (el) 2020-07-31
AU2014236316B2 (en) 2018-11-01
PL2970423T3 (pl) 2019-10-31
EP2970423A2 (en) 2016-01-20
MX2015012912A (es) 2015-12-03
TR201910802T4 (tr) 2019-08-21
CA2906708A1 (en) 2014-09-25
US9580486B2 (en) 2017-02-28
US20140343252A1 (en) 2014-11-20
CN105143253A (zh) 2015-12-09
US10829535B2 (en) 2020-11-10
EP2970423B1 (en) 2019-04-24
NZ751148A (en) 2021-05-28
EP2970441A4 (en) 2016-11-23
JP7227951B2 (ja) 2023-02-22
US20240327485A1 (en) 2024-10-03
ME03437B (me) 2020-01-20
MY202248A (en) 2024-04-19
CY1121823T1 (el) 2020-07-31
JP6450365B2 (ja) 2019-01-09
BR112015022440B1 (pt) 2022-08-16
HRP20190970T1 (hr) 2019-07-26

Similar Documents

Publication Publication Date Title
CL2015002669A1 (es) Polipeptidos que contienen región fc aglicosilada
EP3429996A4 (en) SMALL MOLECULES DIRECTED AGAINST CEREBLON TO IMPROVE THE FUNCTION OF T EFFECTOR LYMPHOCYTES
CL2015000606A1 (es) Polipeptidos que contienen fc con glicosilacion alterada y función efectora reducida.
CR20150329A (es) Inmunoglobulinas heterodiméricas
FR2998570B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
CR20140565A (es) Proteínas de fusión de interleuquina 10 y usos de las mismas
IN2015DN00143A (es)
ECSP12012105A (es) Antídotos de Anticoagulantes
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
CO7111285A2 (es) Composiciones pesticidas y procesos relacionados con ellas
CL2015001472A1 (es) Composiciones y métodos para anticuerpos dirigidos epo.
WO2014206561A8 (en) Novel antibody frameworks
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
EP3049445A4 (en) Interleukin-2 fusion proteins and uses thereof
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
EP3021868A4 (en) Antibodies against chikungunya virus and uses thereof
WO2015058132A3 (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses
CL2015003174A1 (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
DE112014003462A5 (de) Transparente Sonnenschutzmittelzusammensetzungen und deren Verwendung
EA201301090A1 (ru) Антидоты антикоагулянтов
EP3589652A4 (en) RECOMBINANT ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH 1 (PD-1) AND THEIR USES
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
WO2015001045A3 (en) Pro-apoptotic ras and raf peptides